Compare Amgen, Inc. (AMGN) vs Public Storage (PSA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Public Storage — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while Public Storage trades at $320 (market cap $56.28B). The key difference: Amgen, Inc. is far larger — about 3.5× Public Storage's market cap, and Public Storage pays the higher dividend (3.74%). Which is the better fit depends on your goals.
| AMGN | PSA | |
|---|---|---|
Market Cap | $196.12B | $56.28B |
Sector | Health | Real Estate |
52-Week High | $388.16 | $329.64 |
52-Week Low | $271.18 | $258.44 |
Enterprise Value | $241.41B | $70.53B |
Dividend Yield | 2.77% | 3.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Public Storage (PSA) trades at $320.56, up 0.38% with a bullish technical signal. The company demonstrates strong profitability with 39.16% net margins and consistent earnings beats. Recent developments include a $900 million note offering to fund the National Storage Affiliates acquisition and expansion into Canadian markets, signaling growth ambitions. Analyst consensus targets $332.25 with 65.72% hold ratings.
PSA offers stable income with recent dividend payments but faces execution risks from expansion initiatives. Valuation multiples appear elevated with P/E of 33.12, requiring sustained growth to justify premium pricing. The stock's near-term performance hinges on Q2 2026 earnings results due July 29, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
